Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Net Margin (2020 - 2025)

Historic Net Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to 2.18%.

  • Mirum Pharmaceuticals' Net Margin rose 179300.0% to 2.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.78%, marking a year-over-year increase of 237300.0%. This contributed to the annual value of 26.1% for FY2024, which is 615800.0% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Net Margin of 2.18% as of Q3 2025, which was up 179300.0% from 4.59% recorded in Q2 2025.
  • Mirum Pharmaceuticals' Net Margin's 5-year high stood at 1825.37% during Q4 2021, with a 5-year trough of 942.16% in Q3 2021.
  • Its 5-year average for Net Margin is 44.03%, with a median of 50.35% in 2023.
  • The largest annual percentage gain for Mirum Pharmaceuticals' Net Margin in the last 5 years was 7520300bps (2022), contrasted with its biggest fall of -19559200bps (2022).
  • Mirum Pharmaceuticals' Net Margin (Quarter) stood at 1825.37% in 2021, then crashed by -107bps to 130.55% in 2022, then soared by 61bps to 51.27% in 2023, then surged by 53bps to 23.93% in 2024, then skyrocketed by 109bps to 2.18% in 2025.
  • Its Net Margin stands at 2.18% for Q3 2025, versus 4.59% for Q2 2025 and 13.15% for Q1 2025.